BPC-157 10mg
1 capsule 1 to 3 times daily
This compartment-specific action is why clinical trials show 1218% visceral fat reduction with minimal subcutaneous fat loss
J Clin Endocrinol Metab 89:30553061 Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, van Raalte DH (2016) Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men
Future research should focus on the development of additional activators of the SLC7A11/GPX4 pathway with pharmaceutical properties and conduct clinical trials where appropriate
There was a 13% reduction in the composite primary endpoint of cardiovascular death, non-fatal stroke, or non-fatal myocardial infarction (MI) [HR 0.87 (95% CI, 0.78 to 0.97)